Free Review Articles on Bortezomib                                 Metatextbook

Freie Reviews über Bortezomib                                 Look here for Journal Homepages

  • PCD (Multiple myeloma and other plasma cell dyscrasias)
  • Bortezomib
  • Haut (Neoplasia Melanoma)
  • Alcohol
  • Proteasome
  • Ubiquitin
  • Osteoblasts
  • Osteoclasts
  • Osteoporosis
  • Dickkopf1
  • Tipifarnib
  • Lung (Neoplasm)
  • Cetuximab
  • Pemetrexed
  • Transplantation
    • Nr.Year

    OPEN

    		Titleusers

    say

    		rate

    good

    		rate

    bad

    no link

    		Citation
    12009Bortezomib for the treatment of multiple myeloma patients.



    		+-nlHealth Technol Assess 13 Suppl 1(-):29-33 (2009)
    22007Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.



    		+-nlCancer 110(5):1042-9 (2007)
    32011Potential usage of proteasome inhibitor bortezomib (Velcade, PS-341) in the treatment of metastatic melanoma: basic and clinical aspects.



    		+-nlAm J Cancer Res 1(7):913-24 (2011)
    42009Nuclear effects of ethanol-induced proteasome inhibition in liver cells.



    		+-nlWorld J Gastroenterol 15(10):1163-7 (2009)
    52007Myeloma bone disease and proteasome inhibition therapies.



    		+-nlBlood 110(4):1098-104 (2007)
    62008Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature.



    		+-nlBlood 112(5):1593-9 (2008)
    72007Bortezomib-induced peripheral neurotoxicity: still far from a painless gain.



    		+-nlHaematologica 92(10):1308-10 (2007)
    82006A practical update on the use of bortezomib in the management of multiple myeloma.



    		+-nlOncologist 11(1):51-61 (2006)
    92007Clinical impact of bortezomib in frontline regimens for patients with multiple myeloma.



    		+-nlOncologist 12(8):978-90 (2007)
    102007The emerging role of targeted therapy for hematologic malignancies: update on bortezomib and tipifarnib.



    		+-nlOncologist 12(3):281-90 (2007)
    112005Three emerging new drugs for NSCLC: pemetrexed, bortezomib, and cetuximab.



    		+-nlOncologist 10(4):282-91 (2005)
    122011Role of proteasome inhibition in sensitized transplant candidates.



    		+-nlChin Med J (Engl) 124(5):771-4 (2011)



    Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

    All data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.